Screener
BridgeBio Pharma BBIO Reportable Segment — Interest Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total operating costs and expenses | 300,471 | 221,005 |
| Loss from operations | (105,956) | (104,372) |
| Other income (expense), net: | ||
| Interest income | 6,246 | 5,385 |
| Interest expense | (12,942) | (18,121) |
| Noncash interest expense on deferred royalty obligations (1) | (39,873) | (24,020) |
| Loss on extinguishment of debt | — | (21,155) |
| Net loss from equity method investments | (18,283) | (15,556) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's reportable segment — interest income?
- BridgeBio Pharma (BBIO) reported reportable segment — interest income of $6.25M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — interest income changed year-over-year?
- BridgeBio Pharma's reportable segment — interest income increased by 16.0% year-over-year, from $5.39M to $6.25M.
- What does reportable segment — interest income mean?
- Income earned from cash balances, short-term investments, or other interest-bearing assets held by the segment. It reflects the return on the company's liquid capital.
Ask your AI about BridgeBio Pharma's reportable segment — interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude